{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Grade III anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade III neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade III thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade IV thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade III epistaxis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III gastrointestinal bleed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade III acute renal failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III headache"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III aphasia due to laryngeal plasmacytoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III leg/hip pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade III generalized pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade IV hypoglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade IV hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade III pneumonia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III pulmonary edema"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade III pneumonitis/pulmonary infiltrates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III pulmonary hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III hypoxia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade IV dyspnea"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Toxicities were graded using the NCI Common Toxicity Criteria v3.0.","groups":[{"description":"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.\n\nIn patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days following end of treatment (median duration of therapy was 51 days)","title":"Safety and Tolerability of Dasatinib (Grade III-IV Toxicities)","type":"SECONDARY","unitOfMeasure":"participants"}